Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 07/28 10:03:33 pm
99.168 EUR   +1.01%
07/26 MERCK KGAA : Biopharma Innovation Cup Honors Young Scientists
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency A..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at djnews.frankfurt@dowjones.com

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
08:23p MERCK KGAA : MilliporeSigma Starts Construction on $115 Million Multi-faceted Li..
07/26 MERCK KGAA : Biopharma Innovation Cup Honors Young Scientists
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets Around 23% of Ethiopia..
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency Acceptance fo..
07/14 MERCK KGAA : EMD Serono Commits EUR1.5 million to the Grant for Fertility Innova..
07/14 MERCK KGAA : Recent Findings from Merck KGaA Provides New Insights into Fenofibr..
07/13 MERCK KGAA : Advances Water Purification Systems with New High-Throughput Line
07/12 MERCK KGAA : Expands Excipients Portfolio, Adding Polymers for Sustained Release..
07/11 MERCK : and University of Nairobi to Start Medical Oncology Fellowship Program
More news
Sector news : Specialty & Advanced Pharmaceuticals
07:12pDJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
03:28pDJU.S. HOT STOCKS : Hot Stocks to Watch
01:42pDJALEXION PHARMACEUTICALS : Cuts Profit Guidance
01:35pDJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
01:16pDJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
07/06 Late-stage study commences assessing Merck KGaA and Pfizer's avelumab + chemo..
07/05 OneCrinone reproductive treatment approved in Japan
06/24 Sector Licks Its Brexit Wounds
06/24 Eylea Combinations And Array's Play For Melanoma
Advertisement
Financials (€)
Sales 2016 15 088 M
EBIT 2016 3 263 M
Net income 2016 1 669 M
Debt 2016 10 865 M
Yield 2016 1,24%
P/E ratio 2016 24,66
P/E ratio 2017 23,00
EV / Sales 2016 1,56x
EV / Sales 2017 1,40x
Capitalization 12 689 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,5 €
Spread / Average Target 1,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Laszlo Radvanyi Senior Vice President & Head-Research
Crocifissa Attardo Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA9.43%14 044
ABBVIE INC9.55%104 967
BIOGEN INC-5.88%63 183
KYOWA HAKKO KIRIN CO L..-4.93%10 380
JAZZ PHARMACEUTICALS P..0.96%8 584
MALLINCKRODT PLC-9.03%7 422
More Results